Bioterrorism - A Comprehensive Note

Definition

• Goldman-Cecil Medicine, p. 206
• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 206

Historical Background

• Bioweapons have been used for centuries - catapulting plague-infected corpses over city walls (Caffa, 1346), poisoning water supplies, and distributing smallpox-infected blankets to Native Americans in the 18th century.
• Modern programs were developed by the US, USSR, UK, and others during the 20th century. The 1972 Biological Weapons Convention (BWC) prohibited the development, production, and stockpiling of biological weapons, though compliance has been inconsistent.
• Notable modern events include the 1984 Rajneeshee bioterror attack (salmonella in salad bars, Oregon), the 1995 Tokyo subway sarin attack (chemical), and the 2001 US anthrax letter attacks (inhalational anthrax, 22 cases, 5 deaths).

CDC Classification of Bioterrorism Agents

Category A - Highest Priority

• Are easily disseminated or transmitted person-to-person
• Cause high mortality with major public health impact
• May cause public panic and social disruption
• Require special public health preparedness actions

Category B - Second Priority

• Brucella spp. (brucellosis)
• Coxiella burnetii (Q fever)
• Rickettsia prowazekii (typhus fever)
• Chlamydophila psittaci (psittacosis)
• Ricin toxin from Ricinus communis
• Staphylococcus enterotoxin B
• Epsilon toxin of Clostridium perfringens
• Food/water safety threats: Salmonella, E. coli O157:H7, Vibrio cholerae, Shigella
• Alphaviruses (Venezuelan equine encephalitis)

Category C - Emerging Threats

• Hantavirus
• Nipah virus
• Multidrug-resistant Mycobacterium tuberculosis
• Tickborne hemorrhagic fever viruses
• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 206; Goldman-Cecil Medicine, p. 210

Epidemiologic Clues of a Bioterrorist Attack

• A large epidemic with a similar disease or syndrome in a discrete population
• Unusually numerous unexplained deaths
• Disease unusual to the geographic area or transmission season
• Multiple simultaneous or serial epidemics of different diseases in the same population
• Disease outbreaks in noncontiguous areas
• Disease transmitted by a vector not present locally
• A single case of a rare disease (e.g., smallpox)
• Unusual age distribution for a common disease
• Unusual strains, variants, or antimicrobial resistance patterns atypical for the local area
• More severe disease than expected, or failure to respond to standard therapy
• Unusual route of exposure (e.g., inhalational anthrax instead of cutaneous)
• Genetically identical agents isolated from different times or locations
• Parikh's Textbook of Medical Jurisprudence, Forensic Medicine and Toxicology, p. 634; Goldman-Cecil Medicine, p. 207

Key Category A Agents - Clinical Overview

1. Anthrax (Bacillus anthracis)

• Cutaneous anthrax - Most common (95%). Spores enter through skin cuts/abrasions. A painless, pruritic papule appears 1-7 days after exposure, evolves into a vesicle, then an ulcer with a characteristic black eschar ("malignant pustule"). Low mortality with treatment.
• Inhalational anthrax (Woolsorter's disease) - The weaponized form. Spores are inhaled, deposited in mediastinal lymph nodes, and germinate. Biphasic illness: initial flu-like prodrome, then sudden deterioration with mediastinal widening on CXR, hemorrhagic mediastinitis, septicemia, and meningitis. Mortality >80% even with treatment; up to 100% untreated.
• Gastrointestinal anthrax - From ingesting undercooked contaminated meat. Oropharyngeal or abdominal form; high mortality.

2. Smallpox (Variola major)

• Incubation: 12-14 days (range 7-17 days)
• Prodrome: High fever, malaise, prostration, headache, backache
• Rash progression: Maculopapular (Day 1) → papules (Day 2) → vesicles (Day 4-5) → pustules (Day 7) → scabs (Day 14)
• Key feature: Lesions are in the same stage of development at any one time (unlike chickenpox, where different stages coexist); lesions are more prominent on face and extremities (centrifugal distribution)
• Case mortality rate: ≥30%
• No effective antiviral therapy. Vaccination is the cornerstone; the vaccinia-based vaccine is effective if given within 4 days of exposure
• High transmissibility via respiratory droplets makes it the most feared bioweapon. Population immunity has waned since vaccination ended in the US in 1972.

3. Plague (Yersinia pestis)

• Bubonic plague: Flea-bite transmission; painful swollen lymph nodes (buboes), fever; can progress to septicemia
• Pneumonic plague (weaponized form): Inhalation of droplets; rapidly fatal pneumonia; highly contagious person-to-person
• Septicemic plague: Primary bloodstream infection; DIC, ecchymoses ("Black Death")

4. Tularemia (Francisella tularensis)

• Highly infectious: as few as 10 organisms via the aerosol route can cause disease
• Weaponized form causes pneumonia with high fever, non-productive cough, pleuritis
• Also causes ulceroglandular (skin ulcer + lymphadenopathy), oculoglandular, and typhoidal forms
• Treatment: Streptomycin or gentamicin; ciprofloxacin or doxycycline as alternatives

5. Botulism (Clostridium botulinum toxin)

• Most potent toxin known; a single gram could theoretically kill >1 million people
• Weaponized via aerosol or food contamination
• Mechanism: blocks release of acetylcholine at neuromuscular junctions → descending flaccid paralysis
• Clinical features: Ptosis, diplopia, dysarthria, dysphagia ("4 Ds"), then descending weakness, respiratory failure; afebrile, normal mental status, symmetric paralysis - key distinguishing features from Guillain-Barre and other neuropathies
• Diagnosis: Mouse bioassay (toxin protection test); PCR for environmental samples
• Treatment: Equine heptavalent antitoxin (HBAT); supportive care with mechanical ventilation

6. Viral Hemorrhagic Fevers (VHF)

• Incubation: 2-21 days
• Features: Abrupt high fever, myalgias, headache, then hemorrhagic manifestations (petechiae, ecchymoses, frank bleeding from multiple sites), shock, multi-organ failure
• Transmitted via contact with infected blood/body fluids; aerosol transmission possible with some agents
• Case fatality: 9-90% depending on agent
• Management: Supportive; ribavirin active against some arenaviruses (Lassa); anti-Ebola monoclonal antibodies (atoltivimab/maftivimab/odesivimab) now available

Routes of Dissemination

1. Aerosol sprays - Most effective; bypasses natural defenses, delivers agent directly to the respiratory tract (anthrax, smallpox, plague, tularemia)
2. Contamination of food and water - Botulinum toxin, salmonella, cholera
3. Infected vectors - Fleas (plague), mosquitoes
4. Person-to-person transmission - Smallpox, pneumonic plague, VHF
5. Letters or packages - As in 2001 anthrax attacks

Response Framework: Five Phases

1. Preparedness phase - Stockpiling countermeasures (vaccines, antitoxins, antibiotics), training surveillance networks, establishing response protocols
2. Early warning phase - Epidemiologic surveillance; real-time disease reporting systems; laboratory sentinel networks
3. Notification phase - Alert public health authorities, CDC, FBI, local emergency management
4. Response phase - Medical countermeasures, quarantine/isolation, decontamination, mass casualty management
5. Recovery phase - Environmental clean-up, psychological support, investigation, after-action review

Laboratory Diagnosis

• Gram stain, culture, and sensitivity for bacterial agents
• PCR - rapid identification of agent DNA/RNA in environmental and clinical samples
• ELISA and immunofluorescence for toxins and viral antigens
• Mouse bioassay - gold standard for botulinum toxin (type-specific antitoxin protects mice)
• Electron microscopy - for orthopoxviruses (smallpox)
• Level 3/4 BSL laboratories required for most Category A agents
• The LRN (Laboratory Response Network) is the US infrastructure for bioterrorism laboratory diagnosis

Management Principles

Prevention and Preparedness

• International: Biological Weapons Convention (1972), UN Security Council Resolution 1540
• National: Strategic National Stockpile (SNS) - vaccines, antibiotics, antitoxins pre-positioned; CHEMPACK program
• Hospital: Healthcare facility response plans, surge capacity, personal protective equipment protocols
• Vaccination: Smallpox vaccine for first responders; anthrax vaccine (BioThrax) for military personnel
• Surveillance: BioWatch (environmental detection), syndromic surveillance systems

Key Points for Clinical Practice

• Any unusual cluster of pneumonia, especially in healthy young adults without an obvious infectious source, should raise suspicion of aerosolized anthrax, plague, or tularemia
• Suspect smallpox if you see a severe febrile illness followed by a rash with all lesions at the same stage
• Botulism presents with afebrile, descending flaccid paralysis - always check for a food outbreak cluster
• Report any suspected case immediately - early notification is the cornerstone of an effective response
• Physicians are often the first to detect a bioterrorist event through clinical pattern recognition

• Goldman-Cecil Medicine (International Edition), Ch. 19 (Bioterrorism), pp. 206-210
• Parikh's Textbook of Medical Jurisprudence, Forensic Medicine and Toxicology, pp. 633-635
• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 206
• Jawetz, Melnick & Adelberg's Medical Microbiology, 28th ed., Ch. on Bioterrorism Agents
• CDC Bioterrorism Agent Categories
• Bioterrorism: A Public Health Perspective, PMC